The International Status of Cyclocarya paliurus Leaf Polyphenols
Share
Market position in one sentence
青钱柳叶多酚目前不是国际主流大宗植物原料，而是一种源自中国、科研关注度正在上升、已经出现早期国际法规认可，但仍需解决人体证据、法规准入和标准化供应问题的新兴原料。把它宣传成“全球广泛应用的成熟原料”并不准确；把它描述为具有差异化潜力的中国特色植物原料更符合事实。
Cyclocarya paliurus leaf polyphenols are not yet a mainstream global botanical ingredient. They are better described as an emerging China-origin ingredient with growing scientific interest, early international regulatory recognition and significant work still required in human evidence, market authorization and standardized supply. Calling the ingredient widely established worldwide would be inaccurate; positioning it as a differentiated Chinese botanical with development potential is more defensible.
International scientific visibility is growing
青钱柳相关研究已经进入多个国际英文期刊，研究主题涵盖植物化学、代谢调节、肠道菌群、黄酮生物合成、风味代谢组学、提取工艺和微胶囊递送。2024至2026年仍有新论文持续发表，说明青钱柳并非只存在于地方性传统使用叙事中，而是已经成为天然产物和功能食品研究的一个细分主题。
Cyclocarya paliurus research now appears in a range of international English-language journals, covering phytochemistry, metabolic regulation, gut microbiota, flavonoid biosynthesis, taste metabolomics, extraction and microencapsulation. Continued publications from 2024 to 2026 show that the plant has moved beyond a purely local traditional-use narrative and become a defined niche in natural-products and functional-food research.
但论文数量和国际临床影响力仍不能与绿茶多酚、葡萄籽原花青素、姜黄素、白藜芦醇或小檗碱相比。多数作者和样品来源仍集中在中国，临床研究薄弱，研究材料的规格也不统一。这决定了它目前更像“科研驱动的早期原料”，而不是全球品牌已经普遍采用的成熟成分。
Publication volume and international clinical influence remain far below those of green-tea polyphenols, grape-seed proanthocyanidins, curcumin, resveratrol or berberine. Authors and samples are still concentrated in China, clinical evidence is weak, and test-material specifications are inconsistent. This makes Cyclocarya paliurus a research-led emerging ingredient rather than a mature ingredient broadly adopted by global brands.
Australia provides an important regulatory precedent
澳大利亚治疗用品管理局在2023年建立了Cyclocarya paliurus leaf extract dry的成分指南，允许符合要求的原料用于Listed Medicines体系。TGA定义的原料来源于干燥青钱柳叶，经热水提取后冻干，典型提取比为10比1，并规定了外观、粒径、灰分、水分、TLC鉴别、HPLC指纹、槲皮素、总黄酮、多糖、总糖、总多酚以及污染物指标。
Australia’s Therapeutic Goods Administration established a compositional guideline for Cyclocarya paliurus leaf extract dry in 2023, permitting a compliant ingredient for use in listed medicines. The TGA material is produced from dried leaves by aqueous hot-water extraction followed by freeze-drying, with a typical extraction ratio of 10:1. Its guideline covers appearance, particle size, ash, loss on drying, TLC identification, HPLC fingerprinting, quercetin, total flavonoids, polysaccharides, total sugars, total polyphenols and contaminants.
这是青钱柳进入中国以外受监管健康产品体系的重要证明，但不意味着任何青钱柳提取物都可以直接进入澳大利亚市场。原料必须符合当地定义和组成指南，成品还要满足Listed Medicines的产品、生产、标签和证据要求。
This is an important example of Cyclocarya paliurus entering a regulated health-product framework outside China. It does not mean that every Cyclocarya extract can be supplied to Australia automatically. The ingredient must meet the local definition and compositional guideline, while the finished listed medicine remains subject to product, manufacturing, labeling and evidence obligations.
|
比较项目 |
中国2026食品原料 |
澳大利亚TGA原料 |
|
监管用途 |
规定食品类别 |
Listed Medicines |
|
基本工艺 |
热水提取、过滤、浓缩、干燥 |
热水提取后冻干，典型10比1 |
|
总多酚 |
不低于18% |
24%至35% |
|
总黄酮 |
不低于2% |
10%至22% |
|
其他指标 |
总皂苷不低于1.8% |
槲皮素、多糖、总糖及HPLC指纹 |
Chinese approval does not transfer to the United States or Europe
截至2026年9月的本次公开资料检索，没有识别到美国FDA针对青钱柳叶多酚完成的公开GRAS Notice，也没有识别到欧盟针对青钱柳叶多酚的Novel Food授权。这里应当使用“本次检索未识别到”，而不是绝对宣称不存在，因为企业自我GRAS结论、未公开商业资料或其他名称下的历史记录可能不容易通过公开检索发现。
In our search of public information through September 2026, we did not identify a completed public FDA GRAS notice specifically for Cyclocarya paliurus leaf polyphenols or an EU novel-food authorization specifically covering the ingredient. This should be reported as “not identified in our search,” not as an absolute statement that no pathway exists, because private self-GRAS conclusions, non-public commercial files or records under another name may not be readily visible.
对美国市场，企业需要判断其作为普通食品成分还是膳食补充剂成分进入，并核查1994年前的美国销售历史、NDI要求以及具体宣称边界。对欧盟市场，则要核查1997年5月15日前是否具有显著食用历史，否则可能需要Novel Food授权。每个国家都需要单独完成法规判断。
For the United States, a company must determine whether the intended use is in conventional food or dietary supplements and examine pre-1994 marketing history, possible NDI requirements and claim limitations. For the European Union, significant food use before May 15, 1997 must be assessed; otherwise, a novel-food authorization may be required. Each target country needs its own regulatory review.
Commercial use remains concentrated in tea and generic extracts
海外电商和B2B平台可以看到青钱柳叶茶、复配茶、普通10比1提取物、科研用提取物及少量补充剂产品。这证明市场并非完全空白，但平台商品页面不能证明产品销量、法规合规性或真实市场规模。公开市场上也很难判断这些产品是否采用统一的总多酚、总皂苷和总黄酮标准。
International e-commerce and B2B platforms show Cyclocarya paliurus leaf tea, blended herbal tea, generic 10:1 extracts, research extracts and a limited number of supplement products. This demonstrates that the market is not empty, but marketplace listings do not prove sales volume, regulatory compliance or actual market size. It is also difficult to determine whether these products share consistent standards for total polyphenols, saponins and flavonoids.
因此，不宜引用缺乏方法说明的“全球青钱柳市场规模”数字。更可靠的商业判断是：当前需求小而分散，主要由传统茶饮、特色补充剂和新原料研发驱动；未来增长取决于法规路径、人体验证、品牌教育和稳定供应。
Unverified estimates of a global Cyclocarya market should therefore be avoided. A more reliable commercial assessment is that current demand is small and fragmented, driven mainly by traditional tea, specialty supplements and new-ingredient development. Future growth depends on regulatory pathways, human evidence, market education and reliable supply.
What will determine international competitiveness
国际买家最终购买的不是一个科研故事，而是一套可以审核的原料系统。关键文件包括准确植物学名称与部位、产区与采收信息、提取溶剂和流程、规格与检测方法、HPLC指纹、农残和重金属数据、微生物和真菌毒素数据、稳定性、批次记录以及目标市场的法规判断。
International buyers do not ultimately purchase a research story; they purchase an auditable ingredient system. Key documentation includes the correct botanical name and plant part, origin and harvest information, extraction solvent and process, specifications and analytical methods, HPLC fingerprinting, pesticide and heavy-metal data, microbiological and mycotoxin controls, stability, batch records and a regulatory assessment for the intended market.
湖北晟美康已经获得包含青钱柳叶多酚的中国食品生产许可并已正式投产。现阶段最合理的国际定位不是宣称原料已经全球成熟，而是向研发和品牌客户提供一个来自中国、具有明确国内合规基础、可共同推进规格和应用验证的新兴植物原料。具体产品规格及批次数据以正式COA为准。
Hubei Shengmei Kang has obtained a Chinese food production license covering Cyclocarya paliurus leaf polyphenols and has commenced commercial production. The appropriate international position at this stage is not that the ingredient is already globally mature, but that it is an emerging Chinese botanical with a defined domestic compliance foundation that can be developed further with R&D and brand partners. Product specifications and batch-specific data are subject to the official certificate of analysis.
参考资料 References
Australian Therapeutic Goods Administration. Compositional Guideline for Cyclocarya paliurus leaf extract dry. https://www.tga.gov.au/resources/resources/compositional-guidelines/cyclocarya-paliurus-leaf-extract-dry
Australian Therapeutic Goods Administration. Update to listed medicine ingredients in October 2023. https://www.tga.gov.au/news/regulatory-decision-notices/update-listed-medicine-ingredients-october-2023
US FDA GRAS Notice Inventory. https://www.fda.gov/food/generally-recognized-safe-gras/gras-notice-inventory
European Commission Novel Food information. https://food.ec.europa.eu/food-safety/novel-food_en
Shen et al. The phytochemicals and health benefits of Cyclocarya paliurus. Frontiers in Nutrition 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10115952/